medigraphic.com
Órgano Oficial del Hospital Angeles Health System

2009, Number 2

<< Back Next >>

Acta Med 2009; 7 (2)

Detemir in type 2 diabetes mellitus

Palafox CG, Sosa CA

Language: Spanish
References: 37
Page: 96-99
PDF size: 60.83 Kb.


Text Extraction

No abstract


REFERENCES

  1. Polonsky KS, Given BD, Hirsch LJ et al. Abnormal patterns of insulin secretion in non-insulin-dependent diabetes mellitus. N Engl J Med 1988; 31: 1231-1239.

  2. Wajchenberg BL. {beta}-Cell Failure in Diabetes and Preservation by Clinical Treatment. Endoc Rev 2007; 28: 187-218.

  3. Rosenfalck AM, Thorsby P, Kjems L et al. Improved postprandial glycaemic control with insulin aspart in type 2 diabetic patients. Acta Diabetol 2000; 37: 41-46.

  4. Bethel MA, Feinglos MN. Insulin Analogues: New therapies for type 2 diabetes mellitus. Current Diabetes Report 2002; 5: 403-408.

  5. Bell DA. Insulin therapy in diabetes mellitus: How can the currently available injectable insulins be most prudently and efficaciously utilized? Drugs 2007; 67: 1813-1828.

  6. Lepore MA, Pampanelli SI, Fanelli CA et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 2000; 49: 2142-2148.

  7. Kurtzhals PE, Ribel UL. A novel principle of protraction of potential use for basal insulin delivery. Diabetes 1995; 44: 1381-1385.

  8. Kurtzhals PE, Havelund SV, Jonassen IB, Ribel UI, Markussen JA. Mode of action of fatty acid acylated insulins: A novel type of soluble, long-acting insulin analogs. Diabetes 1996; 45(2S): 222A.

  9. Markussen JA, Havelund SV, Krutzhals PE et al. Soluble fatty acid insulins bind to albumin and show protracted action in pigs. Diabetologia 1996; 39: 281-288.

  10. Havelund SV, Ribel UI, Plum AN et al. The mechanism of protraction of insulin Detemir, a long-acting, acylated analogue of human insulin. Diabetes 2004; 53(2S): 109A.

  11. Dea MK, Hamilton-Wessler MA, Ader MA et al. Albumin binning of acylated insulin (NN304) does not deter action to stimulate glucose uptake. Diabetes 2002; 51: 762-769.

  12. Kurtzhals PE, Havelund SV, Jonassen IB, Markussen JA. Effect of fatty acids and selected drugs on the albumin binding of a long-acting, acylated insulin analogue. J Pharm Sci 1997; 86: 1365-1368.

  13. Kurtzhals PE, Schaffer LA, Sorensen AN et al. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes 2000; 49: 999-1005.

  14. Brunner GA, Sendlhofer GE, Wutte AN et al. Pharmacokinetic and pharmacodynamic properties of long-acting insulin analogue NN304 in comparison to NPH insulin in humans. Diabetes 1999; 48 (1S): 286A.

  15. Pieber TR, Wutte, AN, Plank JO et al. Comparison of pharmacodynamic and pharmacokinetic dose-response profiles between insulin Detemir and NPH insulin in subjects with type 2 diabetes. Diabetes 2004; 53(2S): 142A.

  16. Hermansen KJ, Davies ME, Derezinski TA et al. A 26-week, randomized, parallel, treat-to-target trial comparing insulin Detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin naďve people with type 2 diabetes. Diabetes Care 2006; 29: 1269-1274.

  17. Plank JO, Bodenlenz MA, Sinner FR et al. A double-blind, randomized, dose-response study investigating the pharmacodynamic a pharmacokinetic properties of the long-acting insulin analog Detemir. Diabetes Care 2005; 28: 1107-1112.

  18. Klein O, Lynge E, Damholt B, Nosek L, Heise T. Albumin-bound basal insulin analogues (insulin Detemir and NNH344): comparable time-action profiles but less variability than insulin glargina in type 2 diabetes. Diab Obes Metab 2007; 9: 290-299.

  19. Hompesch M, Troupin B, Heise T et al. Time-action profile of insulin Detemir and NPH insulin in patients with type 2 diabetes from different ethnic groups. Diab Obes Metab 2006; 8: 568-573.

  20. Heller SI, Olsen KL, Draeger EB. Lower risk nocturnal hypoglycaemia with insulin Detemir versus NPH insulin in people with diabetes: a meta-analysis of controlled phase III trials. Diabetes 2004; 53(2S): 487A.

  21. Meneghini LF, Rosenberg KH, Koenen C, Marileinen MJ, Luddeke H. Insulin Detemir improves glycaemic control with less hypoglycaemia and no weight gain in patients with type 2 diabetes who were insulin naďve or treated with NPH or insulin glargine: clinical practice experience from a German subgroup of that PREDICTIVE study. Diab Obes Metab 2007; 9: 418-427.

  22. DCCT Research Group. Weight gain associated with intensive therapy in diabetes control and complications trial. Diabetes Care 1988; 11: 567-573.

  23. DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329(14): 977-986.

  24. Makimattila SA, Nikkila K, Yki-Jarvinen HA. Causes of weight gain during insulin therapy with and without metformin in patients with type II diabetes mellitus. Diabetologia 1999; 42: 406-412.

  25. Hellstrom PM, Geliebter Al, Naslund ER et al. Peripheral and central signals in the control of eating in normal, obese and binge-eating human subjects. British Journal of Nutrition 2004; 92(1S): 47-57S.

  26. Dornhorst A, Luddeke H, Sreenan S et al. Insulin Detemir improves glycaemic control without weight gain in insulin-naďve patients with type 2 diabetes; subgroup analysis from the PREDICTIVE (TM) study. International Journal of Clinical Practice 2008; 62: 659-665.

  27. Dornhorst A, Luddeke H, Koenen C et al. PREDICTIVE Study Group Transferring to insulin Detemir from NPH insulin or insulin glargine in type 2 diabetes patients on basal-only therapy with oral antidiabetic drugs improves glycaemic control and reduces weight gain and risk of hypoglycaemia: 14-week follow-up data from PREDICTIVE (TM). Diab Obes Metab 2008; 10: 75-81.

  28. Haak T, Tiengo A, Draeger E, Suntun M, Waldhausl W. Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin Detemir compared to NPH insulin in patients with type 2 diabetes. Diab Obes Metab 2005; 7: 56-64.

  29. Raslova KA, Tamer SC, Claurson PE, Karl DI. Insulin Detemir results in less weight gain that NPH insulin when used in basal-bolus therapy for type 2 diabetes mellitus and this advantage increases with baseline body mass index. Clinical Drug Investigation 2007; 27: 279-285.

  30. Hermansen KJ, Davies ME. Does insulin in Detemir have a role in reducing risk of insulin associated weight gain? Diab Obes Metab 2007; 9: 209-217.

  31. Philis-Tsimikas A. A comparison of once-daily detemir with NPH added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes. Clinical Therapeutics 2006. 28; 10:1569-1581.

  32. International Diabetes Federation; Guideline for Management of Postmeal Glucose, 2007, www.idf.org

  33. Raskin P, Allen E, Hollander P. Initiating insulin therapy en type 2 diabetes. Diabetes Care 2005; 28: 260-265.

  34. Hirsh IB, Bergenstal RM, Parkin CG et al. A real-world approach to insulin therapy in primary care practice. Clinical Diabetes 2005; 23: 78-86.

  35. Jacobsen LV. Pharmacokinetics of insulin detemir in subjects with renal or hepatic impairment. Diabetes 2002; (Suppl 2): A102.

  36. Datos en archivo. NN 304-1243. Novo Nordisk.

  37. Nathan D. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetes Care 2008. 31; 12: 1-11.




2020     |     www.medigraphic.com